Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References Harry Kirsch Chief Financial Officer Financial review and 2022 guidance 20 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation